Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	The Angels Initiative Stroke prevention

Lung Cancer

Free Subscription Articles published in Mol Cancer Ther Retrieve available abstracts of 41 articles: HTML format

Single Articles

July 2022
1. SUN Y, Zhang Y, Schultz CW, Pommier Y, et al
   CDK7 inhibition synergizes with topoisomerase I inhibition in small cell lung cancer cells by inducing ubiquitin-mediated proteolysis of RNA polymerase II.
   Mol Cancer Ther. 2022 Jul 13. pii: 706999. doi: 10.1158/1535-7163.MCT-21-0891.
   PubMed     Abstract available
   
   
   
2. DU Y, Chen Y, Wang Y, Chen J, et al
   HJM-561, a Potent, Selective, and Orally Bioavailable EGFR PROTAC that Overcomes Osimertinib-Resistant EGFR Triple Mutations.
   Mol Cancer Ther. 2022;21:1060-1066.
   PubMed     Abstract available
   
   
   
3. MARTIN AL, Anadon CM, Biswas S, Mine JA, et al
   Olfactory Receptor OR2H1 Is an Effective Target for CAR T Cells in Human Epithelial Tumors.
   Mol Cancer Ther. 2022;21:1184-1194.
   PubMed     Abstract available
   
   
   June 2022
4. WIEDEMEYER WR, Gavrilyuk J, Schammel A, Zhao X, et al
   ABBV-011, A Novel, Calicheamicin-Based Antibody-Drug Conjugate, Targets SEZ6 to Eradicate Small Cell Lung Cancer Tumors.
   Mol Cancer Ther. 2022;21:986-998.
   PubMed     Abstract available
   
   
   
5. ADASHEK JJ, Menta AK, Reddy NK, Desai AP, et al
   Tissue-Agnostic Activity of BRAF plus MEK Inhibitor in BRAF V600-Mutant Tumors.
   Mol Cancer Ther. 2022;21:871-878.
   PubMed     Abstract available
   
   
   
6. COKER EA, Stewart A, Ozer B, Minchom A, et al
   Individualized Prediction of Drug Response and Rational Combination Therapy in NSCLC Using Artificial Intelligence-Enabled Studies of Acute Phosphoproteomic Changes.
   Mol Cancer Ther. 2022;21:1020-1029.
   PubMed     Abstract available
   
   
   May 2022
7. WERR L, Plenker D, Dammert MA, Lorenz C, et al
   CD74-NRG1 Fusions Are Oncogenic In Vivo and Induce Therapeutically Tractable ERBB2:ERBB3 Heterodimerization.
   Mol Cancer Ther. 2022;21:821-830.
   PubMed     Abstract available
   
   
   April 2022
8. MIRZAPOIAZOVA T, Xiao G, Mambetsariev B, Nasser MW, et al
   Correction: Protein Phosphatase 2A as a Therapeutic Target in Small Cell Lung Cancer.
   Mol Cancer Ther. 2022;21:700.
   PubMed    
   
   
   
9. CASAZZA A, Van Helleputte L, Van Renterghem B, Pokreisz P, et al
   PhAc-ALGP-Dox, a Novel Anticancer Prodrug with Targeted Activation and Improved Therapeutic Index.
   Mol Cancer Ther. 2022;21:568-581.
   PubMed     Abstract available
   
   
   
10. KENNEDY GT, Azari FS, Bernstein E, Nadeem B, et al
    A Prostate-Specific Membrane Antigen-Targeted Near-Infrared Conjugate for Identifying Pulmonary Squamous Cell Carcinoma during Resection.
    Mol Cancer Ther. 2022;21:546-554.
    PubMed     Abstract available
    
    
    January 2022
11. JENSEN-PERGAKES K, Tatlock J, Maegley KA, McAlpine IJ, et al
    SAM-Competitive PRMT5 Inhibitor PF-06939999 Demonstrates Antitumor Activity in Splicing Dysregulated NSCLC with Decreased Liability of Drug Resistance.
    Mol Cancer Ther. 2022;21:3-15.
    PubMed     Abstract available
    
    
    December 2021
12. JO H, Yagishita S, Hayashi Y, Ryu S, et al
    Comparative study on the efficacy and exposure of molecular target agents in non-small cell lung cancer PDX models with driver genetic alterations.
    Mol Cancer Ther. 2021 Dec 15. pii: 1535-7163.MCT-21-0371.
    PubMed     Abstract available
    
    
    
13. BREHMER D, Beke L, Wu T, Millar HJ, et al
    Discovery and Pharmacological Characterization of JNJ-64619178, a Novel Small-Molecule Inhibitor of PRMT5 with Potent Antitumor Activity.
    Mol Cancer Ther. 2021;20:2317-2328.
    PubMed     Abstract available
    
    
    October 2021
14. DASILVA JO, Yang K, Surriga O, Nittoli T, et al
    A Biparatopic Antibody-Drug Conjugate to Treat MET-Expressing Cancers, Including Those that Are Unresponsive to MET Pathway Blockade.
    Mol Cancer Ther. 2021;20:1966-1976.
    PubMed     Abstract available
    
    
    September 2021
15. YIN L, Zhang Y, Yin L, Ou Y, et al
    Novel mitochondria-based targeting restores responsiveness in therapeutically resistant human lung cancer cells.
    Mol Cancer Ther. 2021 Sep 28. pii: 1535-7163.MCT-20-1095.
    PubMed     Abstract available
    
    
    
16. JUDD J, Abdel Karim N, Khan H, Naqash AR, et al
    Characterization of KRAS Mutation Subtypes in Non-Small Cell Lung Cancer.
    Mol Cancer Ther. 2021 Sep 13. pii: 1535-7163.MCT-21-0201.
    PubMed     Abstract available
    
    
    
17. JIANG Y, Willmore E, Wedge SR, Ryan AJ, et al
    DNAPK Inhibition Preferentially Compromises the Repair of Radiation-induced DNA Double-strand Breaks in Chronically Hypoxic Tumor Cells in Xenograft Models.
    Mol Cancer Ther. 2021;20:1663-1671.
    PubMed     Abstract available
    
    
    
18. LEI K, Kang SS, Ahn EH, Chen C, et al
    C/EBPbeta/AEP Signaling Regulates the Oxidative Stress in Malignant Cancers, Stimulating the Metastasis.
    Mol Cancer Ther. 2021;20:1640-1652.
    PubMed     Abstract available
    
    
    
19. GILL SJ, Wijnhoven PWG, Fok JHL, Lloyd RL, et al
    Radiopotentiation Profiling of Multiple Inhibitors of the DNA Damage Response for Early Clinical Development.
    Mol Cancer Ther. 2021;20:1614-1626.
    PubMed     Abstract available
    
    
    August 2021
20. LI Y, Zhang Y, Yu X, Liu Q, et al
    SAGE1: a potential target antigen for lung cancer T-cell immunotherapy.
    Mol Cancer Ther. 2021 Aug 31. pii: 1535-7163.MCT-21-0203.
    PubMed     Abstract available
    
    
    
21. MERCER-SMITH AR, Jiang W, Bago JR, Valdivia A, et al
    Cytotoxic Engineered Induced Neural Stem Cells as an Intravenous Therapy for Primary Non-Small Cell Lung Cancer and Triple-Negative Breast Cancer.
    Mol Cancer Ther. 2021 Aug 25. pii: 1535-7163.MCT-21-0109.
    PubMed     Abstract available
    
    
    
22. BASCHNAGEL AM, Elnaggar JH, VanBeek HJ, Kromke AC, et al
    ATR inhibitor M6620 (VX-970) enhances the effect of radiation in non-small cell lung cancer brain metastasis patient derived xenografts.
    Mol Cancer Ther. 2021 Aug 19. pii: 1535-7163.MCT-21-0305.
    PubMed     Abstract available
    
    
    
23. FUJIWARA T, Yakoub MA, Chandler A, Christ AB, et al
    CSF1/CSF1R Signaling Inhibitor Pexidartinib (PLX3397) Reprograms Tumor-Associated Macrophages and Stimulates T-cell Infiltration in the Sarcoma Microenvironment.
    Mol Cancer Ther. 2021;20:1388-1399.
    PubMed     Abstract available
    
    
    
24. SURMAN DR, Xu Y, Lee MJ, Trepel J, et al
    Therapeutic Synergy in Esophageal Cancer and Mesothelioma Is Predicted by Dynamic BH3 Profiling.
    Mol Cancer Ther. 2021;20:1469-1480.
    PubMed     Abstract available
    
    
    
25. JO U, Senatorov IS, Zimmermann A, Saha LK, et al
    Novel and Highly Potent ATR Inhibitor M4344 Kills Cancer Cells With Replication Stress, and Enhances the Chemotherapeutic Activity of Widely Used DNA Damaging Agents.
    Mol Cancer Ther. 2021;20:1431-1441.
    PubMed     Abstract available
    
    
    
26. SMITH RA, Zammit DJ, Damle NK, Usansky H, et al
    ASN004, A 5T4-targeting scFv-Fc Antibody-Drug Conjugate with High Drug-to-Antibody Ratio, Induces Complete and Durable Tumor Regressions in Preclinical Models.
    Mol Cancer Ther. 2021;20:1327-1337.
    PubMed     Abstract available
    
    
    July 2021
27. MIRZAPOIAZOVA T, Xiao G, Mambetsariev B, Nasser MW, et al
    Protein phosphatase 2A as a therapeutic target in small cell lung cancer.
    Mol Cancer Ther. 2021 Jul 12. pii: 1535-7163.MCT-21-0013.
    PubMed     Abstract available
    
    
    June 2021
28. ZHANG D, Hou Z, Aldrich KE, Lockwood L, et al
    A novel Nrf2 pathway inhibitor sensitizes Keap1-mutant lung cancer cells to chemotherapy.
    Mol Cancer Ther. 2021 Jun 22. pii: 1535-7163.MCT-21-0210.
    PubMed     Abstract available
    
    
    
29. KANO H, Ichihara E, Watanabe H, Nishii K, et al
    SHP2 inhibition enhances the effects of tyrosine kinase inhibitors in preclinical models of treatment-naive ALK-, ROS1-, or EGFR-altered non-small-cell lung cancer.
    Mol Cancer Ther. 2021 Jun 22. pii: 1535-7163.MCT-20-0965.
    PubMed     Abstract available
    
    
    
30. TANG TT, Konradi AW, Feng Y, Peng X, et al
    Small Molecule Inhibitors of TEAD Auto-palmitoylation Selectively Inhibit Proliferation and Tumor Growth of NF2-deficient Mesothelioma.
    Mol Cancer Ther. 2021;20:986-998.
    PubMed     Abstract available
    
    
    May 2021
31. SUN D, Nikonova AS, Zhang P, Deneka AY, et al
    Evaluation of the small-molecule BRD4-degrader CFT-2718 in small cell lung cancer and pancreatic cancer models.
    Mol Cancer Ther. 2021 May 27. pii: 1535-7163.MCT-20-0831.
    PubMed     Abstract available
    
    
    February 2021
32. HINZ B, Pruser JL, Ramer R, Wittig F, et al
    The monoacylglycerol lipase inhibitor JZL184 inhibits lung cancer cell invasion and metastasis via the CB1 cannabinoid receptor.
    Mol Cancer Ther. 2021 Feb 25. pii: 1535-7163.MCT-20-0589.
    PubMed     Abstract available
    
    
    
33. KOHLER J, Zhao Y, Li J, Gokhale PC, et al
    ERK inhibitor LY3214996-based treatment strategies for RAS-driven lung cancer.
    Mol Cancer Ther. 2021 Feb 3. pii: 1535-7163.MCT-20-0531.
    PubMed     Abstract available
    
    
    May 2020
34. SENTHILKUMAR G, Fisher MM, Skiba JH, Miller MC, et al
    FGFR inhibition enhances sensitivity to radiation in non-small cell lung cancer.
    Mol Cancer Ther. 2020 May 5. pii: 1535-7163.MCT-19-0931.
    PubMed     Abstract available
    
    
    
35. ZENKE FT, Zimmermann A, Sirrenberg C, Dahmen H, et al
    Pharmacologic Inhibitor of DNA-PK, M3814, Potentiates Radiotherapy and Regresses Human Tumors in Mouse Models.
    Mol Cancer Ther. 2020;19:1091-1101.
    PubMed     Abstract available
    
    
    
36. YAMASHITA D, Minata M, Ibrahim AN, Yamaguchi S, et al
    Identification of ALDH1A3 as a Viable Therapeutic Target in Breast Cancer Metastasis-Initiating Cells.
    Mol Cancer Ther. 2020;19:1134-1147.
    PubMed     Abstract available
    
    
    April 2020
37. KOTANIDES H, Sattler RM, Lebron MB, Carpenito C, et al
    Characterization of 7A5: A Human CD137 (4-1BB) Receptor Binding Monoclonal Antibody with Differential Agonist Properties That Promotes Antitumor Immunity.
    Mol Cancer Ther. 2020;19:988-998.
    PubMed     Abstract available
    
    
    March 2020
38. FUNAZO TY, Tsuji T, Ozasa H, Furugaki K, et al
    Acquired Resistance to Alectinib in ALK-Rearranged Lung Cancer Due to ABCC11/MRP8 Overexpression in a Clinically Paired Resistance Model.
    Mol Cancer Ther. 2020 Mar 26. pii: 1535-7163.MCT-19-0649.
    PubMed     Abstract available
    
    
    
39. ZHANG ZZ, Yu WX, Zheng M, Liao XH, et al
    PIN1 Inhibition Sensitizes Chemotherapy in Gastric Cancer Cells by Targeting Stem Cell-like Traits and Multiple Biomarkers.
    Mol Cancer Ther. 2020;19:906-919.
    PubMed     Abstract available
    
    
    
40. SUN T, Zhang W, Li Y, Jin Z, et al
    Combination Immunotherapy with Cytotoxic T-Lymphocyte-Associated Antigen-4 and Programmed Death Protein-1 Inhibitors Prevents Postoperative Breast Tumor Recurrence and Metastasis.
    Mol Cancer Ther. 2020;19:802-811.
    PubMed     Abstract available
    
    
    February 2020
41. XU D, Liang SQ, Yang H, Bruggmann R, et al
    CRISPR Screening Identifies WEE1 as a Combination Target for Standard Chemotherapy in Malignant Pleural Mesothelioma.
    Mol Cancer Ther. 2020;19:661-672.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: